OTC ANTIHISTAMINE META-ANALYSIS SHOWS 10%-15% MORE PATIENTS OBTAINED RELIEF
This article was originally published in The Tan Sheet
Executive Summary
OTC ANTIHISTAMINE META-ANALYSIS SHOWS 10%-15% MORE PATIENTS OBTAINED RELIEF from cold symptoms in the drug groups than from placebo, FDA consultant Ralph D'Agostino, PhD, Boston University, reported in a Nov. 15 presentation to FDA's Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees. Reporting on the results of a meta-analysis of antihistamine studies in the common cold, D'Agostino said the data "indicate superiority of the antihistamine over the placebo" with a "10%-15% improvement in the drug group versus the placebo group."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning